Persistent glomerular hematuria in living kidney donors confers a risk of progressive kidney disease in donors after heminephrectomy

American Journal of Transplantation

Volumn 10, Issue 7, 2010, Pages 1597-1604

  Kido, R ^a   Shibagaki, Y ^b   Iwadoh, K ^c   Nakajima, I ^c   Fuchinoue, S ^c   Fujita, T ^a   Teraoka, S ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Donation; hematuria; kidney disease; kidney function; renal transplantation

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; DISEASE COURSE; ERYTHROCYTE; FEMALE; GLOMERULAR HEMATURIA; HEMATURIA; HEMINEPHRECTOMY; HUMAN; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; URINALYSIS;

AGED; DISEASE PROGRESSION; DIURESIS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMATURIA; HUMANS; KIDNEY DISEASES; LIVING DONORS; MALE; MIDDLE AGED; NEPHRECTOMY; PATIENT SELECTION; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77954074359     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03077.x     Document Type: Article

References (39)

1. Schena FP. Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney Int 2000 57 : S39 S45.
2. Horvat LD, Shariff SZ, Garg AX. Global trends in the rates of living kidney donation. Kidney Int 2009 75 : 1088 1098.
3. Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: The Declaration of Istanbul. Lancet 2008 372 : 5 6.
4. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet 1992 340 : 807 810.
5. Ramcharan T, Matas AJ. Long-term (20-37 years) follow-up of living kidney donors. Am J Transplant 2002 2 : 959 964.
6. Ibrahim HN, Foley R, Tan L et al. Long-term consequences of kidney donation. N Engl J Med 2009 360 : 459 469.
7. Kido R, Shibagaki Y, Iwadoh K et al. How do living kidney donors develop end-stage renal disease? Am J Transplant 2009 9 : 2514 2519.
8. Sommerer C, Morath C, Andrassy J, Zeier M. The long-term consequences of living-related or unrelated kidney donation. Nephrol Dial Transplant 2004 19 (Suppl 4 iv45 iv47.
9. Fehrman-Ekholm I, Norden G, Lennerling A et al. Incidence of end-stage renal disease among live kidney donors. Transplantation 2006 82 : 1646 1648. (Pubitemid 46035644)
10. Pereira RB, Scheeren J, Castro D et al. Follow-up of kidney donors who developed uremia and went on the waiting list for a transplant: Should they have allocation priority? Transplant Proc 2008 40 : 1012 1013.
11. Okamoto M, Akioka K, Nobori S et al. Short- and long-term donor outcomes after kidney donation: Analysis of 601 cases over a 35-year period at Japanese single center. Transplantation 2009 87 : 419 423.
12. Velosa JA, Offord KP, Schroeder DR. Effect of age, sex, and glomerular filtration rate on renal function outcome of living kidney donors. Transplantation 1995 60 : 1618 1621.
13. Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. Kidney Int 1995 48 : 814 819.
14. Rook M, Hofker HS, van Son WJ, Homan Van Der Heide JJ, Ploeg RJ, Navis GJ. Predictive capacity of pre-donation GFR and renal reserve capacity for donor renal function after living kidney donation. Am J Transplant 2006 6 : 1653 1659.
15. Lee JH, Kim SC, Han DJ et al. Risk factors for MDRD-GFR of less than 60 mL/min per 1.73 m2 in former kidney donors. Nephrology (Carlton) 2007 12 : 600 606.
16. Mandelbrot DA, Pavlakis M, Danovitch GM et al. The medical evaluation of living kidney donors: A survey of US transplant centers. Am J Transplant 2007 7 : 2333 2343.
17. Sobh MA, Moustafa FE, el-Din Saleh MA, Tawfik A, Ghoneim MA. Study of asymptomatic microscopic hematuria in potential living related kidney donors. Nephron 1993 65 : 190 195.
18. Koselj M, Rott T, Kandus A, Vizjak A, Malovrh M. Donor-transmitted IgA nephropathy: Long-term follow-up of kidney donors and recipients. Transplant Proc 1997 29 : 3406 3407.
19. Koushik R, Garvey C, Manivel JC, Matas AJ, Kasiske BL. Persistent, asymptomatic, microscopic hematuria in prospective kidney donors. Transplantation 2005 80 : 1425 1429.
20. Vadivel N, Stankovic A, Rennke HG, Singh AK. Accepting prospective kidney donors with asymptomatic urinary abnormalities: Are we shooting in the dark? Kidney Int 2007 71 : 173 177.
21. Delmonico F. A report of the Amsterdam forum on the care of the live kidney donor: Data and medical guidelines. Transplantation 2005 79 : S53 S66.
22. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009 53 : 982 992.
23. Eknoyan G, Hostetter T, Bakris GL et al. Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003 42 : 617 622.
24. Schramek P, Schuster FX, Georgopoulos M, Porpaczy P, Maier M. Value of urinary erythrocyte morphology in assessment of symptomless microhaematuria. Lancet 1989 2 : 1316 1319.
25. Kohler H, Wandel E, Brunck B. Acanthocyturia-a characteristic marker for glomerular bleeding. Kidney Int 1991 40 : 115 120.
26. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003 139 : 244 252.
27. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 345 : 1291 1297.
28. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003 41 : 1341 1345.
29. Gross O, Weber M, Fries JW, Muller GA. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: Long-term risk, benefit and outcome. Nephrol Dial Transplant 2009 24 : 1626 1630.
30. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003 63 : 2286 2294.
31. Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY. Thin basement membrane nephropathy. Kidney Int 2003 64 : 1169 1178.
32. Kashtan CE. Women with Alport syndrome: Risks and rewards of kidney donation. Nephrol Dial Transplant 2009 24 : 1369 1370.
33. Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001 110 : 434 437.
34. Kashtan CE. The wages of thin. J Am Soc Nephrol 2007 18 : 2800 2802.
35. Jais JP, Knebelmann B, Giatras I et al. X-linked Alport syndrome: Natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 2003 14 : 2603 2610.
36. Kashtan CE. Alport syndrome and the X chromosome: Implications of a diagnosis of Alport syndrome in females. Nephrol Dial Transplant 2007 22 : 1499 1505.
37. Hotta O, Chiba S, Furuta T, Sudou K, Horigome I, Taguma Y. Clinicopathological study of IgA nephropathy in patients with congenitally reduced nephron mass. Clin Nephrol 1995 44 : 362 366.
38. Rahman M, Pressel S, Davis BR et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006 144 : 172 180.
39. Gonzalez E, Gutierrez E, Morales E et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int 2005 68 : 263 270.